Kinnate Biopharma Inc is a clinical-stage precision oncology company focused on the discovery, design, and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The company's pipeline product candidates are; exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma, and other solid tumors, and KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC), a cancer of the bile ducts in the liver, and urothelial carcinoma (UC), a cancer of the bladder lining, as well as other solid tumors.